parasitic%20infections
PARASITIC INFECTIONS
Gastrointestinal parasitic infection symptoms include abdominal pain, diarrhea, dysentery, flatulence, malabsorption and symptoms of biliary obstruction.
It can be caused by protozoan parasites and helminths.
Host susceptibility factors in gastrointestinal parasitic infections are nutritional status, intercurrent disease, pregnancy, immunosuppressive drugs and presence of a malignancy.
Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients.

Parasitic Infections Drug Information

Drug Information

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Axcel Erythromycin ES
erythromycin ethylsuccinate

Indication: Upper & lower resp tract infections caused by Strep pyogenes & Strep pneumoniae; pertussis caused by B...

Indication: Lower & upper rest tract, skin & soft tissue infections, acute otitis media. STD, uncomplicated genita...

Indication: Lower resp tract infections eg, bronchitis & pneumonia, odontostomatological, skin & soft tissue infec...

Indication: Purulent bacterial & trachomatous conjunctivitis caused by Chlamydia trachomatis in adults & childn fr...

Indication: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; otitis me...

Indication: Upper & lower resp tract, ear & oral, eye, veneral, skin & soft tissue, GI infections. Osteomyelit...

Indication: Upper & lower resp tract infections; skin & soft tissue & other infections. Adjunct to antitoxin, ...

Indication: Upper & lower resp tract infections, skin & soft tissue infections, ear & oral infections.

Indication: Upper & lower resp tract infections, skin & soft tissue infections, ENT infections, UTI.

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.